NVGH Vi-CRM197

BIOLOGICAL2 trials

Sponsors

Novartis

Conditions

Typhoid Fever

Phase 1

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

CompletedNCT01123941

NovartisTyphoid Fever

Start: 2010-05-31End: 2010-11-30Updated: 2014-01-17

Phase 2

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

CompletedNCT01438996

NovartisTyphoid Fever

Start: 2011-10-31End: 2011-12-31Updated: 2014-03-24

Related Papers

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.

2011-09-3057 citations